IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF
This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.
1 . An isolated peptide selected from
SGQAYMFPNAPYLPSCLES (SEQ ID No: 41) and QAYMFPNAPYLPSCL (SEQ ID No: 42).
2 .- 13 . (canceled)
14 . A composition comprising the isolated peptide of claim 1 and a physiologically acceptable carrier.
15 . The composition of claim 14 , wherein the composition is a vaccine and further comprises an adjuvant or a carrier, or an antigen presenting cell.
16 . The composition of claim 14 , further comprising an additional WT1 peptide other than said isolated peptide.
17 . The composition of claim 16 , wherein said additional WT1 peptide is selected from the group consisting of: LVRHHNMHQRNMTKL (SEQ ID No: 1), RSDELVRHHNMHQRNMTKL (SEQ ID No: 2), NKRYFKLSHLQMHSR (SEQ ID No: 3), and PGCNKRYFKLSHLQMHSRKHTG (SEQ ID No: 4).
18 . A method of inducing formation and proliferation of a WT1 protein-specific cytotoxic T lymphocyte (CTL), the method comprising contacting a lymphocyte population with the composition of claim 14 , thereby inducing formation and proliferation of a WT1 protein-specific CTL.
19 . A method of inducing formation and proliferation of both (a) a WT1 protein-specific CD8 + lymphocyte; and (b) a CD4 + lymphocyte specific for said WT1 protein, the method comprising contacting a lymphocyte population with the composition of claim 14 , thereby inducing formation and proliferation of both (a) a WT1 protein-specific CD8 + lymphocyte; and (b) a CD4 + lymphocyte specific for said WT1 protein.
20 . A method of treating a subject with a WT1-expressing cancer, the method comprising administering to said subject the composition of claim 14 , thereby treating a subject with a WT1-expressing cancer.
21 . The method of claim 20 , wherein said WT1-expressing cancer is an acute myelogenous leukemia (AML), a malignant mesothelioma, a myelodysplastic syndrome (MDS), a non-small cell lung cancer (NSCLC), an ovarian cancer, or a lymphoma.
22 . A method of reducing an incidence of a WT1-expressing cancer, or its relapse, in a subject, the method comprising administering to said subject the composition of claim 14 , thereby reducing an incidence of a WT1-expressing cancer, or its relapse, in a subject.
23 . The method of claim 22 , wherein said WT1-expressing cancer is an acute myelogenous leukemia (AML), a malignant mesothelioma, a myelodysplastic syndrome (MDS), a non-small cell lung cancer (NSCLC), an ovarian cancer, or a lymphoma.
24 . An antigen-presenting cell comprising the isolated peptide of claim 1 .
25 . A vaccine comprising the antigen-presenting cell of claim 24 .
26 . A nucleic acid molecule encoding the isolated peptide of claim 1 .
27 . A vaccine comprising the nucleic acid molecule of claim 26 .
28 . A vector comprising the nucleic acid molecule of claim 26 .
29 .- 33 . (canceled)
34 . A method of inducing formation and proliferation of a cytotoxic T lymphocyte (CTL) specific for a WT1-expressing cell, the method comprising contacting a lymphocyte population with the composition comprising the isolated peptide SGQARMFPNAPYLPSCLES (SEQ ID NO:39), thereby inducing formation and proliferation of CTL specific for a WT1-expressing cell.
35 . (canceled)
36 . A method of treating a subject with a WT1-expressing cancer, the method comprising administering to said subject the a composition comprising the isolated peptide SGQARMFPNAPYLPSCLES (SEQ ID NO:39), thereby treating a subject with a WT1-expressing cancer.
37 . The method of claim 36 , wherein said WT1-expressing cancer is an acute myelogenous leukemia (AML), a malignant mesothelioma, a myelodysplastic syndrome (MDS), a non-small cell lung cancer (NSCLC), an ovarian cancer, or a lymphoma.
38 - 76 . (canceled)